News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fedora Pharmaceuticals Inc. Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics Against Drug-Resistant Bacteria


9/13/2013 8:53:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EDMONTON, Alberta, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. and its collaborators presented results of preclinical studies demonstrating that FPI-1465 increases the activity of beta-lactam antibiotics against bacteria that have developed resistance through the production of beta-lactamase enzymes. Beta-lactamases destroy the molecular structure of beta-lactam antibiotics, eliminating their antimicrobial activity. FPI-1465 is a beta-lactamase inhibitor (BLI) being investigated as an adjunct to antibiotics for the treatment of patients with difficult-to-treat bacterial infections.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES